Form 4: Celldex Therapeutics CEO Acquires Stock Options

Celldex Therapeutics President & CEO Anthony S. Marucci acquired 375,000 incentive stock options with an exercise price of $34.09.

Summary

• Anthony S. Marucci, President & CEO of Celldex Therapeutics, Inc., was granted 375,000 incentive stock options on June 25, 2026.
• The options have an exercise price of $34.09 per share.
• These options are part of the company's 2021 Omnibus Equity Incentive Plan.
• Vesting begins with 25% on June 25, 2027, with the remainder vesting quarterly over the subsequent 12 quarters.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard executive compensation practice that aligns management with shareholder interests, but does not provide new financial performance data.

Positives

• The CEO's acquisition of stock options signals confidence in the company's future prospects.
• The incentive stock options are designed to align management's interests with those of shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Risks

• The exercise price of $34.09 indicates that the stock price needs to appreciate significantly for the options to be profitable.
• The vesting schedule means the CEO cannot immediately benefit from the full grant, and the value is contingent on continued employment and company performance.

Future Outlook

The grant of incentive stock options suggests management's positive outlook on the company's future performance, as the value of these options is tied to stock price appreciation.

Industry Context

StockSavvy.ai notes that the granting of stock options to senior executives is a common practice in the biotechnology and pharmaceutical sectors to incentivize performance and align executive interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The CEO's acquisition of options may be viewed positively as it aligns his financial interests with stock price appreciation. However, the value is contingent on future performance.
• Employees: The existence of an equity incentive plan for executives can be a signal of the company's growth strategy, potentially benefiting employees through overall company success.
• Management: The CEO is incentivized to drive company performance to realize the value of his stock options.

Next Steps

• The CEO will continue to vest in the stock options over the next 12 quarters, contingent on continued employment and company performance.
• Shareholders will monitor the company's stock performance relative to the $34.09 exercise price.

Key Dates

Keywords

Celldex Therapeutics, CLDX, Form 4, Stock Options, Incentive Stock Option, Executive Compensation, Insider Trading, SEC Filing, Anthony S. Marucci, 2021 Omnibus Equity Incentive Plan